Baxter, M.A.; Spender, L.C.; Walsh, S.; Bray, S.; Skinner, G.; King, S.; Hall, P.S.; Seymour, M.J.; Petty, R.D.; on behalf of the GO2 Investigators.
Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial. Cancers 2023, 15, 2591.
https://doi.org/10.3390/cancers15092591
AMA Style
Baxter MA, Spender LC, Walsh S, Bray S, Skinner G, King S, Hall PS, Seymour MJ, Petty RD, on behalf of the GO2 Investigators.
Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial. Cancers. 2023; 15(9):2591.
https://doi.org/10.3390/cancers15092591
Chicago/Turabian Style
Baxter, Mark A., Lindsay C. Spender, Shaun Walsh, Susan Bray, Gemma Skinner, Sharon King, Peter S. Hall, Matthew J. Seymour, Russell D. Petty, and on behalf of the GO2 Investigators.
2023. "Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial" Cancers 15, no. 9: 2591.
https://doi.org/10.3390/cancers15092591
APA Style
Baxter, M. A., Spender, L. C., Walsh, S., Bray, S., Skinner, G., King, S., Hall, P. S., Seymour, M. J., Petty, R. D., & on behalf of the GO2 Investigators.
(2023). Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial. Cancers, 15(9), 2591.
https://doi.org/10.3390/cancers15092591
